Invitrogen

Human MIA (aa 28-130) Control Fragment Recombinant Protein

Product Details

RP-90572

Applications

Tested Dilution

Publications

Control (Ctrl)

Assay-dependent

Blocking Assay (BLOCK)

Assay-dependent

Product Specifications

Species

Human

Expression System

E. coli

Amino acid sequence

PKLADRKLCADQECSHPISMAVALQDYMAPDCRFLTIHRGQVVYVFSKLKGRGRLFWGGSVQGDYYGDLAARLGYFPSSIVREDQTLKPGKVDVKTDKWDFYC

Tag

His-ABP-tag

Class

Recombinant

Type

Protein

Purity

>80% by SDS-PAGE and Coomassie blue staining

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

≥5.0 mg/mL

Purification

purified

Storage buffer

PBS/1M urea, pH 7.4

Contains

no preservative

Storage conditions

-20°C, Avoid Freeze/Thaw Cycles

Product Specific Information

Highest antigen sequence indentity to the following orthologs: Mouse (91%), Rat (91%).

This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-59957. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.

Target Information

Tumorigenesis is a process that is mediated by a network of membrane, cytosolic and nuclear associated factors, which regulate proliferation and cell-matrix interaction through signaling cascades. The phenotype of malignant melanomas in vivo depends on the global expression of stimulatory or inhibitory factors generated in both the tumors cells and their environment. One example, Melanoma inhibitory activity (cartilage-derived retinoic acid-sensitive protein (CD-RAP), MIA) is a Src homology 3 (SH3)-like domain containing protein that is secreted from chondrocytes and malignant melanoma cells. MIA is translated as a 131-amino acid pro-form and processed into a mature 107-amino acid protein after cleavage of a secretion signal. MIA is expressed during chondrogenesis and in mature chondrocytes, suggesting that MIA is necessary for normal cartilage cell phenotype. MIA mRNA is present in carcinomas of the colon, ovary, kidney, and head/neck, and may represent a marker to monitor melanomic activity.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

References (0)

Have you cited this product in a publication?

Let us know so we can reference it here.

Cite this product

Bioinformatics

Protein Aliases: Melanoma inhibitory activity protein; Melanoma-derived growth regulatory protein